(dur VAL ue mab)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous [preservative free]:
Imfinzi: 120 mg/2.4 mL (2.4 mL); 500 mg/10 mL (10 mL) [contains polysorbate 80]
Brand Names: U.S.
- Antineoplastic Agent, Anti-PD-L1 Monoclonal Antibody
- Antineoplastic Agent, Monoclonal Antibody
Use: Labeled Indications
Urothelial carcinoma, locally advanced or metastatic: Treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
There are no contraindications listed in the manufacturer's labeling.